Can you provide the last earnings date for AUGMEDIX INC?
AUGMEDIX INC (AUGX) last reported earnings on 8/12/2024.
NASDAQ:AUGX • US05105P1075
Past quarterly earnings results for AUGMEDIX INC (AUGX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2024 | -0.13 | -0.14 | 4.41% | -8.33% | 13.664M | 13.909M | -1.76% | 26.75% |
| Q1 2024 | -0.12 | -0.14 | 12.20% | 14.29% | 13.471M | 13.634M | -1.20% | 39.91% |
| Q4 2023 | -0.09 | -0.10 | 11.76% | 40.00% | 12.68M | 12.715M | -0.28% | 44.91% |
| Q3 2023 | -0.10 | -0.12 | 16.56% | 42.56% | 11.767M | 11.653M | 0.98% | 49.71% |
| Q2 2023 | -0.12 | -0.13 | 9.50% | 40.00% | 10.78M | 10.579M | 1.90% | 47.07% |
| Q1 2023 | -0.14 | -0.16 | 10.00% | 12.50% | 9.628M | 9.549M | 0.83% | 37.74% |
| Q4 2022 | -0.15 | -0.16 | 4.09% | - | 8.75M | 8.684M | 0.76% | 32.98% |
| Q3 2022 | -0.17 | - | 8.38% | 7.86M | 7.907M | -0.59% | 39.61% | |
| Q2 2022 | -0.20 | -0.16 | -26.50% | -17.65% | 7.33M | 7.481M | -2.02% | 41.78% |
| Q1 2022 | -0.16 | -0.16 | -2.86% | - | 6.99M | 7.041M | -0.72% | 45.93% |
| Q4 2021 | -0.15 | -0.16 | 4.97% | - | 6.58M | 6.525M | 0.84% | 44.93% |
| Q3 2021 | -0.19 | -0.11 | -77.40% | - | 5.63M | 5.734M | -1.81% | 32.47% |
| Q2 2021 | -0.17 | -0.19 | 12.28% | - | 5.17M | 5.282M | -2.12% | 38.61% |
| Q1 2021 | - | - | 4.79M | - | 20.65% | |||
| Q4 2020 | - | - | 4.54M | - | - | |||
| Q3 2020 | - | - | 4.25M | - | - | |||
| Q2 2020 | - | - | 3.73M | - | - | |||
| Q1 2020 | - | - | 3.97M | - | - |
Notes
AUGMEDIX INC (AUGX) last reported earnings on 8/12/2024.
AUGMEDIX INC (AUGX) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, AUGMEDIX INC (AUGX) has beaten EPS estimates in 4 out of 4 releases.